NeurogesX, Cowen Royalty enter $40M royalty agreement

NeurogesX Inc. has entered into a $40 million royalty financing agreement with Cowen Healthcare Royalty Partners for the Qutenza patch, a dermal delivery system containing prescription strength capsaicin. Cowen Royalty can receive all of NeurogesX's royalties and sales milestones under the company's agreement with Astellas Pharma Europe, but NeurogesX retains economics related to U.S. sales. Release

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.